Shares of Canopy Growth Corporation (CGC 63.38%) have rocketed higher this week, according to data from S&P Global Market Intelligence. The Canadian cannabis producer is up over 100% after Vice President Kamala Harris called for cannabis to be decriminalized as quickly as possible. Investors have taken this in stride and aggressively bought the stock.As of 3:17 p.m. ET on Friday, March 22, shares of Canopy Growth are up 135.1% this week. Here's why.A path to legalization in the United States?In the State of ...

Shares of Canopy Growth (NASDAQ:CGC) stock are surging higher following the German government’s decision to legalize marijuana for adults, effective as of April 1. CGC has now more than doubled this week.With the approval, Canopy expects growth for its Storz & Bickel (S&B) brand, which produces medically approved vaporizers in Germany. Canopy acquired S&B in 2018 for about $157 million. Two of its vaporizers, the VOLCANO MEDIC 2 and the MIGHTY+ MEDIC, received European Union Medical Device Regulations (MDR) ...

德国大麻合法化影响 - 德国部分合法化大麻使用对加拿大公司的股价产生了巨大影响[3] - 德国将允许成年人携带最多25克大麻，家中最多存放50克，私人财产上最多种植三株大麻[4] - 德国市场对这些公司的现有曝光度也是一个关键因素[6]

Removal of narcotic status for cannabis expected to accelerate growth of the German medical cannabis market  SMITHS FALLS, ON, March 22, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), a world-leading diversified cannabis company, celebrates the German government's final approval legalizing cannabis, as well as advancing a clear victory for enhanced medical cannabis access. As of April 1, 2024, cannabis will officially be recognized as a non-narcot ...

Investors will always continue to chase weak stocks that are poorly rated for the chance at contrarian success. Yet, most times it is best to follow the herd when Wall Street repeatedly raises the warning flag on a given stock. That’s as true for Nasdaq stocks to avoid as it is for NYSE shares and shares that trade over-the-counter.Remember, Wall Street employs hundreds and hundreds of analysts whose sole job is to analyze companies and sectors. Those analysts have access to the most up-to-date information ...

Canopy Growth (NASDAQ:CGC) is looking like a key beneficiary amid rising calls for federal marijuana policy reform. As of this writing, CGC stock has gained more than 10% on Wednesday. For the past five days, shares are up by more than 40%.Late last week, Vice President Kamala Harris stated that the U.S. Drug Enforcement Administration (DEA) must reconsider its stance on marijuana, calling the current policy “absurd.” In a White House meeting with a group of individuals who received marijuana pardons under ...

加拿大大麻行业 - 加拿大大麻行业在全球市场上引起了投资者的关注[1] 技术分析和风险管理 - 技术分析和风险管理对于在大麻市场中的投资至关重要[2] Tilray, Inc. - Tilray, Inc. 是国际大麻市场的领先先锋，主要专注于分销、生产、种植和研究大麻[3] - Tilray在多个国家拥有强大的市场影响力，特别是在美国，拥有战略性州份的零售店[4]

大麻股票市场 - 投资者可能期待大选后大麻股票的表现[1] - 美国总统拜登在国情咨文中提倡大麻改革，可能对大选和大麻股票产生重大影响[2] - 大众对大麻合法化的支持达到历史最高水平，两党都不愿意得罪选民[3] Scotts Miracle-Gro公司 - Scotts Miracle-Gro公司虽然不是纯粹的大麻股票，但其业务对植物行业有明显影响[4] - Scotts Miracle-Gro公司在过去一年中表现不稳定，但在某些季度超过了盈利预期[6] - 分析师预计Scotts Miracle-Gro公司在2025年将实现每股收益3.68美元，目前被评为中等买入，高端价格目标为70美元[7] Canopy Growth公司 - Canopy Growth公司被认为是大麻股票中的高风险投资，目前市场预期不高[10] - Canopy Growth公司在过去一年中财务表现不佳，但分析师对其未来表现持乐观态度[11] Tilray公司 - Tilray公司虽然股价有所下跌，但分析师预计其销售额将在未来几年内增长[13] - Tilray公司在上一财年第四季度实现每股亏损7美分，但较之前三个季度有显著改善[14] - 分析师预计Tilray公司在2025年的销售额将达到8.8555亿美元，目前被评为中等买入，高端价格目标为4.10美元[15]

Cannabis stocks surged Monday after Vice President Kamala Harris called on the Drug Enforcement Administration (DEA) to reschedule marijuana “as quickly as possible.” Cannabis is currently a Schedule 1 narcotic, the same classification as heroin, a point Harris called “absurd” and “patently unfair.”In a meeting at the White House with a group who had received pardons for various marijuana-related charges, Harris made special mention of the administration’s efforts into rescheduling marijuana, including the ...

大麻重新排定影响 - Canopy Growth股价在Harris副总统呼吁联邦政府加快大麻重新排定后飙升19.2%[1] - Harris在白宫举行了关于大麻改革的圆桌讨论，称目前将大麻与海洛因一样列为I类毒品是“荒谬”和“显然不公平”[2] - 大麻重新排定为III类毒品不会使其在美国联邦层面合法化，Canopy Growth仍将被禁止进入美国市场和维持在纳斯达克交易所上市[2] - 重新排定大麻可能使Canopy Growth更容易与美国公司合作，尤其有助于Canopy创建一个美国控股公司Canopy USA，从而能够行使Canopy Growth收购多家美国大麻公司的权利[3] 投资建议 - 尽管重新排定大麻将有助于Canopy Growth，但我认为现在并不是购买Canopy Growth股票的明智选择，其他一些在美国已经盈利的大麻股票也将受益[4] - 风险厌恶的投资者最好完全避开大麻股票，积极的投资者应该能够找到比Canopy Growth更具吸引力的股票[5]